Positions

Overview

  • Dr. Roberson is a neurologist and neuroscientist whose research is focused on age-related neurodegenerative disorders. He received his A.B. with highest honors from Princeton University, then earned his Ph.D in neuroscience and M.D. with high honors at Baylor College of Medicine where he studied molecular mechanisms of learning and memory. He completed a residency in neurology at the University of California San Francisco, where he also served as Chief Resident in Neurology. After residency, he completed a clinical fellowship in behavioral neurology at UCSF and resumed basic research at the Gladstone Institute of Neurological Disease. He joined the faculty at UAB in 2008.

    Dr. Roberson's laboratory investigates mechanisms and therapeutic approaches to Alzheimer's disease and frontotemporal dementia, and he directs the Center for Neurodegeneration and Experimental Therapeutics. He is also active in clinical research and patient care. He directs the UAB Alzheimer’s Disease Center, leads clinical trials, and cares for patients with memory disorders and dementia at the Kirklin Clinic.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Alzheimer’s disease risk gene BIN1 induces Tau-dependent network hyperexcitability.  eLife.  9:1-25. 2020
    2020 Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials.  Neurology.  94:e2384-e2395. 2020
    2020 Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases.  American Journal of Human Genetics.  106:632-645. 2020
    2020 Alzheimer’s disease risk gene BIN1 induces Tau-dependent network hyperexcitability 2020
    2020 Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration.  Nature Medicine.  26:387-397. 2020
    2020 Human tau pathology transmits glial tau aggregates in the absence of neuronal tau.  Journal of Experimental Medicine.  217. 2020
    2020 A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity.  Neurobiology of Disease.  134. 2020
    2020 Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients with Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.  JAMA Neurology.  77:215-224. 2020
    2020 β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade.  Science Translational Medicine.  12. 2020
    2020 Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration.  Alzheimer's and Dementia.  16:91-105. 2020
    2020 Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.  Alzheimer's and Dementia.  16:11-21. 2020
    2020 Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint..  Alzheimer's and Dementia.  16:11-21. 2020
    2020 Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.  Alzheimer's and Dementia.  16:49-59. 2020
    2020 Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort.  Alzheimer's and Dementia.  16:60-70. 2020
    2020 Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases.  Alzheimer's and Dementia.  16:118-130. 2020
    2020 Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.  Alzheimer's and Dementia.  16:37-48. 2020
    2020 Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium.  Alzheimer's and Dementia.  16:79-90. 2020
    2020 Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.  Alzheimer's and Dementia.  16:106-117. 2020
    2019 Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations.  Acta Neuropathologica Communications.  7. 2019
    2019 A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data.  Scientific Reports.  9. 2019
    2019 A blood-based signature of cerebrospinal fluid Aβ 1–42 status.  Scientific Reports.  9. 2019
    2019 Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies 2019
    2019 Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways.  Scientific Reports.  9. 2019
    2019 Multimodal Hippocampal Subfield Grading For Alzheimer’s Disease Classification.  Scientific Reports.  9. 2019
    2019 Non-coding variability at the APOE locus contributes to the Alzheimer’s risk.  Nature Communications.  10. 2019
    2019 Nonlinear Z-score modeling for improved detection of cognitive abnormality 2019
    2019 Predicting Alzheimer’s disease progression using multi-modal deep learning approach.  Scientific Reports.  9. 2019
    2019 Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics.  Scientific Reports.  9. 2019
    2019 The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory.  Nature Communications.  10. 2019
    2019 Neurodegenerative Disease–Associated Variants in TREM2 Destabilize the Apical Ligand-Binding Region of the Immunoglobulin Domain.  Frontiers in Neurology.  10. 2019
    2019 Pathogenic Tau Impairs Axon Initial Segment Plasticity and Excitability Homeostasis.  Neuron.  104:458-470.e5. 2019
    2019 Non-Coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases 2019
    2019 Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2).  Nature Genetics.  51:1423-1424. 2019
    2019 Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia.  Molecular Neurobiology.  56:4916-4924. 2019
    2019 Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Workflow for Research and Clinical Brain PET Applications 2019
    2019 Medical decision-making in progressive supranuclear palsy: A comparison to other neurodegenerative disorders.  Parkinsonism and Related Disorders.  61:77-81. 2019
    2019 Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.  Neurobiology of Disease.  124:152-162. 2019
    2019 Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.  Nature Genetics.  51:414-430. 2019
    2019 Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.  Parkinsonism and Related Disorders.  60:138-145. 2019
    2019 Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications.  Journal of Alzheimer's Disease.  70:1241-1257. 2019
    2019 Genome sequencing for early-onset or atypical dementia: High diagnostic yield and frequent observation of multiple contributory alleles.  Cold Spring Harbor molecular case studies.  5. 2019
    2018 Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states.  Scientific Reports.  8. 2018
    2018 Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease.  Scientific Reports.  8. 2018
    2018 Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images.  Scientific Reports.  8. 2018
    2018 Sex-specific genetic predictors of Alzheimer’s disease biomarkers.  Acta Neuropathologica.  136:857-872. 2018
    2018 Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.  Nature Communications.  9. 2018
    2018 Sex-specific association of apolipoprotein e with cerebrospinal fluid levels of tau.  JAMA Neurology.  75:989-998. 2018
    2018 Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency.  Molecular Neurodegeneration.  13. 2018
    2018 Shared Functions of Perirhinal and Parahippocampal Cortices: Implications for Cognitive Aging.  Trends in Neurosciences.  41:349-359. 2018
    2018 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery..  Anesthesiology.  128:728-744. 2018
    2018 Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis 2018
    2018 Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease 2018
    2017 Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer's Disease via Fusion of Clinical, Imaging and Omic Features.  Scientific Reports.  7. 2017
    2017 Genetic influences on cognition in progressive supranuclear palsy.  Movement Disorders.  32:1764-1771. 2017
    2017 Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty.  Scientific Reports.  7. 2017
    2017 18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.  Annals of Neurology.  82:622-634. 2017
    2017 Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.  Nature Genetics.  49:1373-1384. 2017
    2017 Transethnic genome-wide scan identifies novel Alzheimer's disease loci.  Alzheimer's and Dementia.  13:727-738. 2017
    2017 Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects.  Journal of Neural Transmission.  124:721-738. 2017
    2017 Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.  JAMA Neurology.  74:557-566. 2017
    2017 Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia 2017
    2017 Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer's disease.  Scientific Reports.  7. 2017
    2017 Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease.  Neurobiology of Aging.  49:216.e7. 2017
    2016 Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.  Annals of Neurology.  80:858-870. 2016
    2016 Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.  Movement Disorders.  31:1574-1577. 2016
    2016 Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.  Parkinsonism and Related Disorders.  28:29-35. 2016
    2016 Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.  Parkinsonism and Related Disorders.  28:41-48. 2016
    2016 Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test.  Genes, Brain and Behavior.  15:588-603. 2016
    2016 Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.  Nature Communications.  7. 2016
    2016 Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults.  JAMA Neurology.  73:721-732. 2016
    2016 Assessment of the genetic variance of late-onset Alzheimer's disease.  Neurobiology of Aging.  41:200.e13-200.e20. 2016
    2016 Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.  Movement Disorders.  31:742-747. 2016
    2016 Alzheimer's disease risk polymorphisms regulate gene expression in the ZCWPW1 and the CELF1 loci.  PLoS ONE.  11. 2016
    2016 A novel Alzheimer disease locus located near the gene encoding tau protein.  Molecular Psychiatry.  21:108-117. 2016
    2015 Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses.  Alzheimer's and Dementia.  11:1439-1451. 2015
    2015 The Alzheimer's disease risk factor CD2AP maintains blood-brain barrier integrity.  Human Molecular Genetics.  24:6667-6674. 2015
    2015 Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease 2015
    2015 Association of long runs of homozygosity with Alzheimer disease among African American individuals.  JAMA Neurology.  72:1313-1323. 2015
    2015 O3-06-01: Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.  Alzheimer's and Dementia.  11:P230-P230. 2015
    2015 Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study.  PLoS Medicine.  12. 2015
    2015 Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE.  Nature Communications.  6. 2015
    2015 Effects of exercise on progranulin levels and gliosis in progranulin-insufficient mice.  eNeuro.  2. 2015
    2015 Rarity of the alzheimer disease-protective APP A673T variant in the United States.  JAMA Neurology.  72:209-216. 2015
    2015 Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.  Blood.  125:591-599. 2015
    2015 DNA methylation slows effects of C9orf72 mutations.  Neurology.  84:1616-1617. 2015
    2015 Noradrenergic dysfunction in Alzheimer's disease.  Frontiers in Neuroscience.  9. 2015
    2015 Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer’s disease 2015
    2014 Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia 2014
    2014 MicroRNA-124 modulates social behavior in frontotemporal dementia.  Nature Medicine.  20:1381-1383. 2014
    2014 Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study.  JAMA Neurology.  71:1394-1404. 2014
    2014 ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects.  Journal of Clinical Investigation.  124:981-999. 2014
    2014 AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (bret) assays for identification of Tau-Fyn sh3 interaction inhibitors for Alzheimer disease.  Journal of Biomolecular Screening.  19:1338-1349. 2014
    2014 Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial.  Lancet Neurology.  13:676-685. 2014
    2014 Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD.  Journal of Experimental Medicine.  211:1937-1945. 2014
    2014 Seizure resistance without parkinsonism in aged mice after tau reduction.  Neurobiology of Aging.  35:2617-2624. 2014
    2014 The dendritic hypothesis for Alzheimer's disease pathophysiology.  Brain Research Bulletin.  103:18-28. 2014
    2013 Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice.  Annals of Internal Medicine.  158:5352-5362. 2013
    2013 Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in alzheimer's disease.  Journal of Cell Science.  126:1278-1286. 2013
    2013 Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development.  Alzheimer's and Dementia.  9:176-188. 2013
    2013 The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier).  Alzheimer's and Dementia.  9:189-198. 2013
    2012 Challenges and opportunities for characterizing cognitive aging across species.  Frontiers in Aging Neuroscience.  4. 2012
    2012 Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis.  Nature Genetics.  44:1349-1354. 2012
    2012 Mouse models of frontotemporal dementia.  Annals of Neurology.  72:837-849. 2012
    2012 Usp14 Deficiency Increases Tau Phosphorylation without Altering Tau Degradation or Causing Tau-Dependent Deficits.  PLoS ONE.  7. 2012
    2012 Novel late-onset Alzheimer disease loci variants associate with brain gene expression..  Neurology.  79:221-228. 2012
    2012 Mouse models of Alzheimer's disease.  Brain Research Bulletin.  88:3-12. 2012
    2012 Evidence for a role of the rare p.A152T variant in mapt in increasing the risk for FTD-spectrum and Alzheimer's diseases.  Human Molecular Genetics.  21:3500-3512. 2012
    2011 Geriatric epilepsy: Research and clinical directions for the future.  Epilepsy and Behavior.  22:103-111. 2011
    2011 Contemporary approaches to Alzheimer's disease and frontotemporal dementia..  Methods in Molecular Biology.  670:1-9. 2011
    2011 Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling..  Methods in Molecular Biology.  670:245-262. 2011
    2011 Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.  Nature Genetics.  43:436-443. 2011
    2011 Amyloid-β/fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of alzheimer's disease 2011
    2011 Contemporary approaches to Alzheimer's disease and frontotemporal dementia.  Methods in Molecular Biology.  670:1-9. 2011
    2011 Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: Depletion of calcium-dependent proteins and inhibitory hippocampal remodeling.  Methods in Molecular Biology.  670:245-262. 2011
    2011 Step-by-step in situ hybridization method for localizing gene expression changes in the brain.  Methods in Molecular Biology.  670:207-230. 2011
    2010 Beyond diagnosis: What biomarkers are teaching us about the "bio"logy of Alzheimer disease.  Annals of Neurology.  67:283-285. 2010
    2009 Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease 2009
    2008 Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease 2008
    2008 Abnormal social behaviors in mice lacking Fgf17.  Genes, Brain and Behavior.  7:344-354. 2008
    2007 Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease.  Neuron.  55:697-711. 2007
    2007 Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model.  Science.  316:750-754. 2007
    2006 100 Years and counting: Prospects for defeating Alzheimer's disease.  Science.  314:781-784. 2006
    2006 Frontotemporal demetia.  Current Neurology and Neuroscience Reports.  6:481-489. 2006
    2006 Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease.  Neuron.  51:703-714. 2006
    2005 Frontotemporal dementia progresses to death faster than Alzheimer disease.  Neurology.  65:719-725. 2005
    2005 Frontotemporal lobar degeneration: Demographic characteristics of 353 patients.  Archives of Neurology.  62:925-930. 2005
    2003 Polyneuropathy following gastric bypass surgery [6].  American Journal of Medicine.  115:679-680. 2003
    2001 Memory-forming chemical reactions.  Reviews in the Neurosciences.  12:41-50. 2001
    2000 MAPK regulation of gene expression in the central nervous system.  Acta Neurobiologiae Experimentalis.  60:377-394. 2000
    1999 A biochemical blueprint for long-term memory.  Learning and Memory.  6:381-388. 1999
    1999 The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus 1999
    1998 Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation 1998
    1998 A role for superoxide in protein kinase C activation and induction of long-term potentiation.  Journal of Biological Chemistry.  273:4516-4522. 1998
    1998 Protected-site phosphorylation of protein kinase C in hippocampal long- term potentiation.  Journal of Neurochemistry.  71:1075-1085. 1998
    1996 Transient activation of cyclic AMP-dependent protein kinase during hippocampal long-term potentiation.  Journal of Biological Chemistry.  271:30436-30441. 1996
    1996 A biochemist's view of long-term potentiation.  Learning and Memory.  3:1-24. 1996
    1995 Regulation of adenylyl cyclase in LTP.  Behavioral and Brain Sciences.  18:485-485. 1995
    1995 Regulation of adenylyl cyclase in LTP.  Behavioral and Brain Sciences.  18:485-486. 1995
    1992 Ca2+-induced persistent protein kinase C activation in rat hippocampal homogenates 1992
    1988 Identification of an insulin-like factor in astrocyte conditioned medium.  Brain Research.  460:60-67. 1988
    Aberrant regulation of a poison exon caused by a non-coding variant in Scn1a-associated epileptic encephalopathy
    Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants.  PLoS Genetics.  8:e1002707-e1002707.

    Book

    Year Title Altmetric
    2011 Alzheimer's Disease and Frontotemporal Dementia 2011

    Chapter

    Year Title Altmetric
    2017 Frontotemporal Dementia.  141-175. 2017
    2016 Animal models of dementia.  77-93. 2016
    2011 Preface 2011
    2009 Animal models of dementia.  131-141. 2009
    2007 Molecular aspects of memory dysfunction in Alzheimer’s disease.  245-293. 2007

    Research Overview

  • Alzheimer's disease, frontotemporal dementia, and related disorders

    • Principal Investigator On

  • The Progranulin C-Terminal Domain and AAV-Progranulin Gene Therapy for Frontotemporal Dementia  awarded by National Institute on Aging/NIH/DHHS 2021 - 2024
  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Clinical Core  awarded by MAYO CLINIC 2019 - 2024
  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Clinical Core  awarded by MAYO CLINIC 2019 - 2024
  • BIN1, Interneuron Activity, and Network Dysfunction in Alzheimer Disease  awarded by National Institute on Aging/NIH/DHHS 2018 - 2023
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”).  awarded by Washington University 2018 - 2022
  • Toward Therapeutic Approaches to TREM2-R47H in Alzheimer's Disease  awarded by Alzheimer's Drug Discovery Foundation 2019 - 2022
  • Optimizing Progranulin Gene Therapy for Frontotemporal Dementia  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2020 - 2021
  • Circadian Changes in Network Excitability and Alzheimer Disease Pathogenesis  awarded by National Institute on Aging/NIH/DHHS 2019 - 2021
  • Validation of Online Methods to Predict and Monitor Cognitive Decline  awarded by University of California, San Francisco 2018 - 2021
  • Tau-Fyn Interaction and Alzheimer's Disease  awarded by National Institute on Aging/NIH/DHHS 2020 - 2021
  • Therapeutic Strategies in Mouse Models of FTD Due to Progranulin Insufficiency  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2017 - 2020
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University 2013 - 2020
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”)  awarded by THE WASHINGTON UNIVERSITY 2018 - 2020
  • Private Grant  awarded by BIOGEN IDEC, INC. 2017 - 2020
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin Mutations  awarded by National Institute on Aging/NIH/DHHS 2017 - 2019
  • Causes, Treatment, and Prevention of Corticobasal Degeneration  awarded by University of California, San Francisco 2014 - 2018
  • Private Grant  awarded by AVID RADIOPHARMACEUTICALS 2014 - 2018
  • Developing Inhibitors Of Tau-SH3 Interactions As Treatments For Alzheimer's Disease And Hyperexcitability  awarded by WESTON BRAIN INSTITUTE 2017 - 2018
  • Private Grant  awarded by ALECTOR, INC. 2016 - 2018
  • Development of Inhibitors of the Tau-Fyn Interaction For the Treatment of Alzheimer's Disease  awarded by BRIGHT FOCUS FOUNDATION 2015 - 2018
  • Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study  awarded by American College of Radiology 2016 - 2018
  • Therapeutic Strategies in Mouse Models of FTD Due to Progranulin Insufficiency (Consortium for Frontotemporal Dementia Research)  awarded by THE BLUEFIELD PROJECT TO CURE FRONTOTEMPORAL DEMENTIA 2017
  • Consortium for Frontotemporal Dementia Research  awarded by University of California, San Francisco 2008 - 2017
  • BIN1 and Tau Interactions Regulating Neuronal Calcium  awarded by Alzheimer's Association 2014 - 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • Investigating the Impact of Cognition on Functional Ability in PSP  awarded by CUREPSP 2015 - 2017
  • Mechanisms for the Benefit of Tau Reduction in Alzheimer Disease Models  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2017
  • Targeting the Tau-Fyn Interaction in Alzheimer's Disease  awarded by WESTON BRAIN INSTITUTE 2016 - 2017
  • Private Grant  awarded by C2N DIAGNOSTICS, LLC 2015 - 2016
  • Mechanisms of Frontotemporal Dementia Like Behavior in Progranulin Deficient Mice  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2016
  • Weston Advisor Fellowship  awarded by WESTON BRAIN INSTITUTE 2015 - 2016
  • Tau and Glutamatergic Synapses in Frontotemporal Dementia  awarded by National Institute on Aging/NIH/DHHS 2013 - 2016
  • Molecular Mechanisms of Aging-Related Neuronal Dysfunction in Progranulin-Insufficient Mice  awarded by American Federation for Aging Research 2014 - 2015
  • Epileptiform Activity in Neurodegenerative Disease  awarded by STEPHEN BECHTEL JR. FUND 2009 - 2014
  • Characterizing an Inducible Model for the Protective Effects of Tau Reduction  awarded by American Health Assistance Foundation 2010 - 2013
  • Private Grant  awarded by ALLON THERAPEUTICS 2010 - 2013
  • Tau and Fyn in Alzheimer's Disease Pathogenesis  awarded by ALZHEIMER'S OF CENTRAL ALABAMA 2012
  • The Role of Tau in Neurodegeneration  awarded by STEPHEN BECHTEL JR. FUND 2009 - 2012
  • Mechanisms for Tau Involvement in Alzheimer's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2008 - 2012

    • Investigator On

  • Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population  awarded by National Human Genome Research Institute/NIH/DHHS 2020 - 2025
  • Identifying Therapeutic Targets That Confer Synaptic Resilience to Alzheimer's Disease  awarded by National Institute on Aging/NIH/DHHS 2018 - 2023
  • Circadian Dysfunction and Neurodegenerative Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2022
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2022
  • UAB Training Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Targeting Rho Kinases for Alzheimer's Disease Therapeutics  awarded by National Institute on Aging/NIH/DHHS 2017 - 2022
  • Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2021
  • Private Grant  awarded by EISAI, INC. 2013 - 2021
  • Global Alzheimer’s Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease  awarded by University of Southern California 2019 - 2021
  • Private Grant  awarded by BIOGEN, INC. 2018 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study  awarded by University of Southern California 2019 - 2020
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)  awarded by University of Southern California 2016 - 2020
  • Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People with Alzheimer Dementia and Traumatic Brain Injury  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2016 - 2020
  • Private Grant  awarded by ABBVIE INC 2018 - 2020
  • Private Grant  awarded by ABBVIE INC 2017 - 2020
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2017 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2016 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2015 - 2019
  • Private Grant  awarded by NEURIM PHARMACEUTICALS 2017 - 2019
  • Abnormal Late Endosomal Trafficking in Frontotemporal Dementia due to Progranulin Mutations  awarded by National Institute on Aging/NIH/DHHS 2017 - 2019
  • Reducing Tau as a Therapeutic Strategy for Improving Cognitive Dysfunction in Parkinson's Disease  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2016 - 2019
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2018
  • Private Grant  awarded by H. LUNDBECK A/S 2014 - 2018
  • Private Grant  awarded by ASSUREX HEALTH INC. 2016 - 2018
  • Circadian Dysfunction and GSK3 in Neurodegenerative Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2018
  • Private Grant  awarded by AVANIR PHARMACEUTICALS, INC. 2016 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Functional Change in Mild Cognitive Impairment  awarded by National Institute on Aging/NIH/DHHS 2010 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study: A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California 2015 - 2016
  • Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)  awarded by University of Southern California 2015 - 2016
  • Alzehimer's Disease Neuroimaging Initiative (ADNI)  awarded by University of California, San Diego 2005 - 2016
  • Training Program in the Neurobiology of Cognition and Cognitive Disorders  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of California, San Diego 2012 - 2016
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - The LEARN Study A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of California, San Diego 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Private Grant  awarded by TRANSITION THERAPEUTICS INC. 2013 - 2015
  • Preclinical Test for the Efficacy of Adrenergic Agents in Treatment of AD  awarded by National Institute on Aging/NIH/DHHS 2012 - 2015
  • A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-To-Moderate Alzheimer's Disease  awarded by University of California, San Diego 2010 - 2014
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2009 - 2013
  • Amyloid Imaging, VMCI, and Analysis for ADNI  awarded by University of California, San Diego 2009 - 2012

    • Education And Training

  • Doctor of Medicine, Baylor College of Medicine 1999
  • Doctor of Philosophy in Neuroscience, Baylor College of Medicine 1997
  • Baylor College of Medicine, Internship 2000
  • UCSF Medical Center Neurology, Residency 2003
  • UCSF Medical Center, Postdoctoral Fellowship 2005

    • Full Name

  • Erik Roberson